Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
The Effects of Ethyl-alpha-Guanido-methyl Ethanoate on Skin Reactions Form Glatiramer Acetate
Status: Archived
University of Nebrasaka Medical Center
mi
from
Omaha, NE
The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
The Effects of Ethyl-alpha-Guanido-methyl Ethanoate on Skin Reactions Form Glatiramer Acetate
Status: Archived
Updated: 1/1/1970
University of Nebrasaka Medical Center
mi
from
Omaha, NE
Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)
Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)
Status: Archived
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)
Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Atlanta, GA
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Atlanta, GA
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Evanston, IL
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Evanston, IL
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Ayer, MA
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ayer, MA
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Detroit, MI
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Detroit, MI
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Asheville, NC
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Asheville, NC
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Bend, OR
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bend, OR
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Salt Lake City, UT
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Salt Lake City, UT
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Clinical Research Facility
mi
from
Beloit, WI
JCV Antibody Program (STRATIFY-1)
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Beloit, WI
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Birmingham Clinical Site 136
mi
from
Birmingham, AL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Birmingham Clinical Site 136
mi
from
Birmingham, AL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Tucson Clinical Site 133
mi
from
Tucson, AZ
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Tucson Clinical Site 133
mi
from
Tucson, AZ
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Aurora Clinical Site 132
mi
from
Aurora, CO
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Aurora Clinical Site 132
mi
from
Aurora, CO
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Fort Collins Clinical Site 123
mi
from
Fort Collins, CO
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Fort Collins Clinical Site 123
mi
from
Fort Collins, CO
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Fairfield Clinical Site 110
mi
from
Fairfield, CT
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Fairfield Clinical Site 110
mi
from
Fairfield, CT
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Ormond Beach Clinical Site 129
mi
from
Ormond Beach, FL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Ormond Beach Clinical Site 129
mi
from
Ormond Beach, FL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Sarasota Clinical Site 116
mi
from
Sarasota, FL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Sarasota Clinical Site 116
mi
from
Sarasota, FL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Northbrook Clinical Site 135
mi
from
Northbrook, IL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Northbrook Clinical Site 135
mi
from
Northbrook, IL
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Fort Wayne Clinical Site 111
mi
from
Fort Wayne, IN
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Fort Wayne Clinical Site 111
mi
from
Fort Wayne, IN
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Indianapolis Clinical Site 121
mi
from
Indianapolis, IN
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Indianapolis Clinical Site 121
mi
from
Indianapolis, IN
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Kansas City Clinical Site 119
mi
from
Kansas City, KA
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Kansas City Clinical Site 119
mi
from
Kansas City, KA
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Lenexa Clinical Site 127
mi
from
Lenexa, KA
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Lenexa Clinical Site 127
mi
from
Lenexa, KA
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Detroit Clinical Site 104
mi
from
Detroit, MI
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Detroit Clinical Site 104
mi
from
Detroit, MI
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Farmington Hills Clinical Site 126
mi
from
Farmington Hills, MI
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Farmington Hills Clinical Site 126
mi
from
Farmington Hills, MI
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Lebanon Clinical Site 115
mi
from
Lebanon, NH
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Lebanon Clinical Site 115
mi
from
Lebanon, NH
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Albuquerque Clinical Site 106
mi
from
Albuquerque, NM
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Albuquerque Clinical Site 106
mi
from
Albuquerque, NM
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Charlotte Clinical Site 125
mi
from
Charlotte, NC
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Charlotte Clinical Site 125
mi
from
Charlotte, NC
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
HighPoint Clinical Site 128
mi
from
HighPoint, NC
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
HighPoint Clinical Site 128
mi
from
HighPoint, NC
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Raleigh Clinical Site 103
mi
from
Raleigh, NC
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Raleigh Clinical Site 103
mi
from
Raleigh, NC
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Akron Clinical Site 112
mi
from
Akron, OH
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Akron Clinical Site 112
mi
from
Akron, OH
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Knoxville Clinical Site 134
mi
from
Knoxville, TN
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Knoxville Clinical Site 134
mi
from
Knoxville, TN
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Houson Clinical Site 113
mi
from
Houston, TX
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Houson Clinical Site 113
mi
from
Houston, TX
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Round Rock Clinical Site 107
mi
from
Round Rock, TX
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Round Rock Clinical Site 107
mi
from
Round Rock, TX
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Seattle Clinical Site 118
mi
from
Seattle, WA
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Seattle Clinical Site 118
mi
from
Seattle, WA
Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study
Status: Archived
The Vascular Group, PLLC
mi
from
Albany, NY
Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study
Status: Archived
Updated: 1/1/1970
The Vascular Group, PLLC
mi
from
Albany, NY
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Betaseron Pregnancy Registry
Betaseron Pregnancy Registry
Status: Enrolling
Updated:  12/31/1969
INC Research
mi
from
Wilmington, NC
Betaseron Pregnancy Registry
Betaseron Pregnancy Registry
Status: Enrolling
Updated: 12/31/1969
INC Research
mi
from
Wilmington, NC
Click here to add this to my saved trials
Biomarkers in Multiple Sclerosis
NINDS Biomarkers in Multiple Sclerosis Study (BioMS)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Biomarkers in Multiple Sclerosis
NINDS Biomarkers in Multiple Sclerosis Study (BioMS)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [(11)C]PBR28 in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [(11)C]PBR28 in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cannabis for Spasticity in Multiple Sclerosis
Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study
Status: Enrolling
Updated:  12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
Cannabis for Spasticity in Multiple Sclerosis
Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study
Status: Enrolling
Updated: 12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Status: Enrolling
Updated:  12/31/1969
Outcome Sciences, Inc
mi
from
Cambridge, MA
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Status: Enrolling
Updated: 12/31/1969
Outcome Sciences, Inc
mi
from
Cambridge, MA
Click here to add this to my saved trials
Effects of Training on Central Auditory Function in Multiple Sclerosis
Effects of Training on Central Auditory Function in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Effects of Training on Central Auditory Function in Multiple Sclerosis
Effects of Training on Central Auditory Function in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Investigative Site 3132
mi
from
Scottsdale, AZ
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Investigative Site 3132
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Investigative Site 3115
mi
from
Sacramento, CA
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Investigative Site 3115
mi
from
Sacramento, CA
Click here to add this to my saved trials